108,345 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 108,345 shares of the biopharmaceutical company's stock, valued at approximately $4,891,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.14% of PTC Therapeutics as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PTCT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of PTC Therapeutics by 0.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,681 shares of the biopharmaceutical company's stock worth $2,967,000 after buying an additional 205 shares during the period. Arizona State Retirement System boosted its holdings in shares of PTC Therapeutics by 1.1% during the fourth quarter. Arizona State Retirement System now owns 20,095 shares of the biopharmaceutical company's stock worth $907,000 after acquiring an additional 219 shares during the period. Choreo LLC increased its stake in shares of PTC Therapeutics by 2.0% during the fourth quarter. Choreo LLC now owns 11,961 shares of the biopharmaceutical company's stock worth $541,000 after purchasing an additional 240 shares during the period. Summit Investment Advisors Inc. lifted its holdings in PTC Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,968 shares of the biopharmaceutical company's stock worth $360,000 after purchasing an additional 253 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its position in PTC Therapeutics by 78.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 270 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Royal Bank of Canada boosted their price target on PTC Therapeutics from $57.00 to $58.00 and gave the company an "outperform" rating in a research note on Wednesday, May 7th. Cantor Fitzgerald dropped their price target on PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Barclays dropped their target price on shares of PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Morgan Stanley restated an "overweight" rating and set a $70.00 price objective (up from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. Finally, Scotiabank started coverage on PTC Therapeutics in a research note on Friday, March 7th. They set a "sector perform" rating and a $55.00 target price for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $63.75.

PTC Therapeutics Price Performance

NASDAQ PTCT traded up $1.86 on Tuesday, reaching $50.69. The company had a trading volume of 1,420,581 shares, compared to its average volume of 864,685. The business has a 50 day moving average of $46.35 and a two-hundred day moving average of $47.61. The firm has a market cap of $4.02 billion, a price-to-earnings ratio of -8.53 and a beta of 0.52. PTC Therapeutics, Inc. has a fifty-two week low of $28.72 and a fifty-two week high of $58.38.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, beating the consensus estimate of $0.85 by $9.19. The business had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $437.16 million. The firm's revenue for the quarter was down 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.20) EPS. As a group, research analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Insider Buying and Selling at PTC Therapeutics

In other news, CEO Matthew B. Klein sold 2,804 shares of PTC Therapeutics stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $48.74, for a total transaction of $136,666.96. Following the completion of the transaction, the chief executive officer now directly owns 273,234 shares in the company, valued at $13,317,425.16. This trade represents a 1.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephanie Okey sold 5,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $54.00, for a total transaction of $270,000.00. Following the sale, the director now directly owns 8,867 shares of the company's stock, valued at approximately $478,818. The trade was a 36.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,034 shares of company stock valued at $1,405,767. Corporate insiders own 5.50% of the company's stock.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.